A team of American researchers has been able to prevent the accumulation of toxic proteins that cause Alzheimer's disease in the brain. To date, tests have been carried out on laboratory mice, but they could soon be tested on humans, according to RTE. The new vaccine contains DNA encoding a beta-amyloid protein segment. In the study, the vaccine elicited an immune response that not only reduced the production of beta-amyloid by 40%, but also reduced protein production by 50%. Research has been conducted on mice that have been genetically engineered to develop the equivalent of Alzheimer's rodent disease, says adevarul.ro.
"This study is the result of a decade of research that has repeatedly demonstrated that this vaccine can reliably and reliably identify animal models of what we think can cause Alzheimer's disease," Dr. Roger Rosenberg, Research Director, Director of the Alzheimer's University Center in Texas, quoted agerpres.ro. "I think we are approaching testing this therapy for humans," he said. The main obstacle to the development of effective anti-Alzheimer's vaccines was to find ways to introduce them into the body.
The earlier experimental vaccine, developed in early 2000, caused some brain tumors in some patients when tested in humans. The new vaccine is injected into the skin instead of the muscle, resulting in another type of immune response. If the effects observed in mice will be repeated in humans, this vaccine should be "of great therapeutic value," said the researchers. "If the onset of the illness could be postponed for five years, it would be enormous for patients and their families," says co-author Doris Lambracht-Washington, another team member of the University of Texas team, "The number of dementia cases could drop by half," . Many medicines for cerebral amyloid protein are stored and developed or are clinically tested. But an effective vaccine would be a better strategy, according to researchers at the University of Texas. It would be cheaper and cheaper. Beginning this year, the same team of scientists found the exact point where the molecule became harmful, but the "crowds" had not yet been formed in the brain.
Scientists are also working on a spinal fluid test that can detect abnormal proteins before symptoms of the disease develop. Such a test could identify people who have no symptoms yet but have a high level of tau and amyloid in the brain. Patients identified by this test could then be candidates for treatment with the vaccine. "The more you wait, the less it will be. Once these boards and branches are formed, it can be too late," explains Dr. Rosenberg. The research results were published in Alzheimer's research and therapy. So far, it is known that two types of toxic proteins play a key role in the development of Alzheimer's – beta – amyloid disease and yours. Beta-amyloid and your brain accumulate in the brain and cause nerve cell destruction. Some research suggests that these two are linked, a beta-amyloid that promotes the formation of "agglomerations" caused by your protein.